

Fund Symbols: I: HGHIX A: HGHAX C: HGHXC F: HGHFX R3: HHRX R4: HGHSX R5: HGHTX Y: HGHYX

A Healthy Way to Invest for Growth

The Hartford Healthcare Fund seeks attractive investment opportunities as consumers increase health-care spending and innovations continue at a rapid pace.

The Health-Care Revolution

The health-care sector is undergoing dramatic changes that will impact everything from the drugs we take to the way patients' medical records are shared. Aging demographics globally and rising prosperity in emerging-market nations will drive even greater demand for lifesaving drugs, innovative procedures, and disruptive medical technology.

Pipeline to Innovation

With innovation and breakthroughs taking place across the globe, the Fund uses a broadly diversified, global approach that seeks to identify companies with the greatest opportunities in areas including biotechnology, medical technology, health services, and pharmaceuticals.

Backed by Size, Scale, and Experience

Wellington Management, the Fund's sub-adviser, is one of the largest health-care managers in the world with more than \$63 billion in assets (as of Dec. 31, 2017)*; portfolio managers on the Fund average 15 years of experience following health-care stocks.

Strong Performance Relative to the Broad Market


Based on All Monthly Rolling 5-Year Returns Since Inception (6/1/00-3/31/18)

OUTPERFORMED

the S&P 500 Index

100%
OF THE TIME

Over all monthly rolling
5-YEAR PERIODS



Source: Morningstar, 4/18

Past performance is not indicative of future results. The performance shown above is index performance. Indices are unmanaged and not available for direct investment.

* Firm assets include assets under management and non-discretionary assets.

NOT FDIC INSURED • MAY LOSE VALUE • NO BANK GUARANTEE

hartfordfunds.com

888-843-7824

@hartfordfunds

hartfordfunds.com/linkedin

Overall I-Share Morningstar Rating*



Out of 128 products in the Health Category Based on Risk-Adjusted Returns (as of 3/31/18)

Portfolio Managers From Sub-Adviser Wellington Management:


Jean M. Hynes, CFA
Senior Managing Director
Global Industry Analyst
Professional Experience Since 1993

Ann C. Gallo
Senior Managing Director
Global Industry Analyst
Professional Experience Since 1987

Robert L. Deresiewicz
Senior Managing Director
Global Industry Analyst
Professional Experience Since 1983

The portfolio managers are supported by the full resources of the firm.

Growth of a \$10,000 Investment (5/1/00-3/31/18)



Industry Exposure (%)

Medical Technology	26
Health Care Services	23
Mid Cap Biopharmaceutical	20
Large Cap Biopharmaceutical	20
Small Cap Biopharmaceutical	11

Based on sub-adviser's classification of health care subsectors, which includes combining biotechnology and pharmaceuticals in terms of capitalization: biopharma small-cap, biopharma mid-cap, and biopharma large-cap. Excludes cash. May not total to 100% due to rounding.

Top Ten Holdings (%)

UnitedHealth Group, Inc.	5.70
Medtronic plc	4.32
Bristol-Myers Squibb Co.	4.19
Allergan plc	3.25
Boston Scientific Corp.	2.83
Stryker Corp.	2.70
Thermo Fisher Scientific, Inc.	2.55
Eli Lilly & Co.	2.39
AstraZeneca plc	2.33
Abbott Laboratories	2.16
% of Portfolio	32.42

Average Annual Total Returns

Performance (%) as of 3/31/18	YTD	1 Year	3 Year	5 Year	10 Year	Since Inception (5/1/2000)
Hartford Healthcare Fund I	1.62	9.94	5.41	16.04	13.33	11.73
S&P Composite 1500 Health Care Index	-0.50	12.35	6.17	14.47	12.68	---
Morningstar Health Category Average	1.61	14.01	3.31	14.83	13.21	---

Expenses³ Net: 1.03% Gross: 1.03%

Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted. For more current performance information to the most recent month ended, please see hartfordfunds.com.

Share Class Inception: 8/31/06. Class I-share performance prior to its inception date reflects Class A-share performance (excluding sales charges) and operating expenses.

* Class I-Share Star Ratings: 3-year 4 stars out of 128 products, 5-year 4 stars out of 120 products, and 10-year 3 stars out of 97 products for the period ended herein. Other share classes may have different ratings. The Morningstar Rating™ for funds, or "star rating", is calculated for funds and separate accounts with at least a 3-year history. Exchange-traded funds and open-ended mutual funds are considered a single population for comparative purposes. Star rating based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a managed product's monthly excess performance (without adjusting for any sales load, if applicable), placing more emphasis on downward variations and rewarding consistent performance. 5 stars are assigned to the top 10%, 4 stars to the next 22.5%, 3 stars to the next 35%, 2 stars to the next 22.5%, and 1 star to the bottom 10%. Overall Morningstar Rating is derived from a weighted average of the performance figures associated with its 3-, 5-, and 10-year (if applicable) Morningstar Rating metrics. For more information about the Morningstar Fund Ratings, including their methodology, please go to global.morningstar.com/managerdisclosures. © 2018 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

Important Risks: Investing involves risk, including the possible loss of principal. There is no guarantee a fund will achieve its stated objective. Security prices fluctuate in value depending on general market and economic conditions and the prospects of individual companies. • Risks of focusing investments on the healthcare related sector include regulatory and legal developments, patent considerations, intense competitive pressures, rapid technological changes, potential product obsolescence, and liquidity risk. • Foreign investments may be more volatile and less liquid than U.S. investments and are subject to the risk of currency fluctuations and adverse political and economic developments. These risks may be greater for investments in emerging markets. • Small- and mid-cap securities can have greater risks and volatility than large-cap securities.

¹ S&P 500 Index is a market capitalization-weighted price index composed of 500 widely held common stocks.

² S&P Composite 1500 Health Care Index is a modified capitalization-weighted index based on United States headquartered health care companies.

³ Expenses as shown in the fund's most recent prospectus. Gross and Net expenses are the same.

Investors should carefully consider a fund's investment objectives, risks, charges and expenses. This and other important information is contained in the fund's prospectus and summary prospectus, which can be obtained by visiting hartfordfunds.com. Please read it carefully before investing.

Mutual funds are distributed by Hartford Funds Distributors, LLC (HFD), Member FINRA. Advisory services are provided by Hartford Funds Management Company, LLC (HFMC). Certain funds are sub-advised by Wellington Management Company LP. HFD and HFMC are not affiliated with any sub-adviser. 205994 MF7347_0418